Birds's Eye
Technicals
MovingAverage
Candlestick
PivotPoint
Fin Statements
Beta&Vols
Tech Charts
Future/OptionFundamental Analysis of Glenmark Pharmaceuticals Ltd. - Growth / Value Index
GLENMARK - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 6.94
Very Expensive - Price to Intrinsic Value of 3.33
Price to Book Ratio of 6.12 suggesting that it is very expensive
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Price to Earning | 68.98 | 41.53 | 330.59 % | ||
| Price to Book | 6.13 | 4.91 | 49.37 % | 2.71 | |
| Price to Sales | 3.90 | 3.26 | 49.35 % | ||
| Enterprise Value to EBITDA Multiple | 21.07 | -17.82 % |
GLENMARK - Profitability Highlights
Profitability Analysis
Net profit has jumped from negative to positive
EBITDA is continuously increasing for last 3 Years
Very Low Dividend Yield of 0 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Return On Equity | 8.88 | 11.83 | 164.78 % | 0.530 | |
| Return On Asset | 4.90 | 6.52 | 165.35 % | 0.292 | |
| Net Profit Margin | 5.65 | 7.86 | 164.77 % | 1.44 | |
| Operating Profit Margin | 59.46 | 12.45 | 1408.84 % | 17.78 | |
| EBITDA Margin | 13.16 | 15.71 | 63.56 % | 8.69 |
Highlights
| Market Cap | 512222 M |
| Enterprise Value | 518330 M |
| Price/Book TTM | 6.13 |
| Outstanding Share | 282200 K |
| Float/ Outstanding Share | 50.17% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 4.21 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 6.00 |
| Altman Z Score | 6.45 |
| Sloan Ratio | 0.117 |
| Peter Lynch Fair Value | 0 |
GLENMARK - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Tsr Growth Index - Poor Score of 26.72
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 13342.00 (Cr) | 12.77 % | 0.253 % |
| Gross Profit | 8723.03 (Cr) | 122.61 % | 4.10 % |
| EBITDA | 1756.15 (Cr) | 84.44 % | 41.71 % |
| Net Profit | 753.69 (Cr) | 173.04 % | 907.96 % |
| EPS | 26.31 | 169.73 % | NA |
GLENMARK - Stability Highlights
Stability Analysis
Tsr Stability Index - Good Score of 67.19
Altman Z Score of 6.44 suggests good Stability
Paid More Than 50% of Debt, Heading towards debt free
Debt to equity ratio has decreased and is lowest in last five years
Company is unable to generate enough free cash to support the business.
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|
| Debt to Equity Ratio | 0.258 | -58.88 % | 0.258 | |
| Cash Ratio | 0.286 | 0.202 % | ||
| Quick Ratio | 1.05 | 24.33 % | 1.05 | |
| Shareholders Equity | 55.14 | 0.881 % | ||
| Debt to EBITDA | 1.09 | -74.86 % |
Historical Valuation Ratios of Glenmark Pharmaceuticals Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Glenmark Pharmaceuticals Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Glenmark Pharmaceuticals Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Glenmark Pharmaceuticals Ltd.
Historical Solvency Ratios
Loading ...